ArticleBiotechnology for biofuels and bioproducts2025
Enhanced bioproduction and processing of mandelic acid enantiomers: towards a sustainable platform for high-value pharmaceutical and polymer applications.
Article in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMandelic acid (MA) is a high-value chiral platform molecule with broad applications in pharmaceutical synthesis, cosmetic formulations, and polymer production. Conventional chemical synthesis is limited by harsh reaction conditions, poor enantioselectivity, and environmental concerns. Microbial biosynthesis offers a sustainable and stereoselective alternative; however, its industrial application is constrained by low titres, suboptimal productivity, and inefficient downstream recovery. This study reports an engineered microbial chassis that enables enhanced biosynthesis of MA enantiomers with integrated downstream compatibility.
resultsThe biosynthetic potential of Escherichia coli was harnessed through targeted metabolic engineering and pathway optimisation for the biosynthesis of (R)- and (S)-MA. Batch fermentations in rich medium produced 1.6 g/L (R)-MA and 1.8 g/L (S)-MA. Transitioning to fed-batch cultivation in defined minimal medium, under non-optimised conditions, increased titres to 2.9 g/L; ee = 99% for (R)-MA and 5.7 g/L; ee = 93% for (S)-MA, representing the highest reported in vivo titres of MA enantiomers achieved in E. coli to date. A two-step downstream process comprising solvent extraction and crystallisation enabled the recovery of MA at high purity (> 99.0%), with recovery efficiencies of 84% for (S)-MA and 77% for (R)-MA. To validate the functional utility of bio-based MA, SAMMA, a sulfuric acid condensation polymer with documented antiviral and contraceptive properties, was synthesised from both bio-based and commercial MA. Additionally, mandelide, a monomer precursor for the biodegradable polystyrene analogue polymandelide (PM), was synthesised to illustrate the platform's relevance to sustainable polymer applications.
conclusionsThis study establishes a robust proof of concept for a microbial platform enabling enantioselective MA biosynthesis from renewable carbon sources. Through the integration of metabolic engineering, downstream process development and application-driven validation, this platform lays the foundation for a scalable and industrially relevant bioproduction strategy. Aligned with the principles of green chemistry and the circular bioeconomy, this approach offers a sustainable and environmentally responsible route to high-value chiral chemicals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.